Abbott and Astellas dismiss Omnicef violation case.
With local companies facing stress in domestic operations, valuations are down.
Indian government has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics.
Deals worth nearly $17 billion have got cancelled including -- the $14.5 billion Reliance-LyondellBasell deal, the $2 billion Reliance-Value Creation transaction, the $12 million PVR-DT Cinemas deal and the $130 million Wockhardt-Abbott Laboratories deal.
Foreign lenders to Wockhardt have succeeded in stalling the debt-ridden pharmaceutical company's attempts to sell its nutrition business to Abbott Laboratories.
US-based Abbott Laboratories has sued Sun Pharmaceutical Industries and Ranbaxy Laboratories in courts there for challenging the patents of its cholesterol-lowering drugs, Niaspan and TriCor, respectively, in separate infringement suits.
The court's stand is expected to help Wockhardt conclude the deal within a month's time.
In a fresh round of patent battle over the launch of generic drugs in the US market, domestic pharmaceutical majors Orchid, Sun Pharma and Ranbaxy Laboratories have been sued by Cima Labs, Otsuka Pharmaceutical Co and Abbott Laboratories, respectivel
Abbott Laboratories is suing India's Ranbaxy Laboratories as well as Israel's Teva and Sandoz of the Novartis group, in Chicago for allegedly violating its patents protecting Omnicef, a drug used to treat ear, throat and skin infections.
Ranbaxy Laboratories has received approval from the U.S. Food and Drug Administration to manufacture and market Clarithromycin XL 1,000 mg tablets.
Pharmaceutical company Ranbaxy Laboratories said on Monday its UK subsidiary has won a patent case over solvent-free clarithromycin and that it has launched the drug.
According to analysts, Glenmark will have to pay a penalty of $16 million, following the latest verdict.
Several companies, including Indian units of Abbott Laboratories and Pfizer Inc, and domestic firms like Cipla Ltd and Macleods Pharmaceuticals, went to the Delhi High Court to try to get the ban lifted.
The health ministry has formed a committee to consider raising the number of drugs deemed essential and subject to price caps.
The branding initiative coincides with the company's expansion.
A copy of the letter dated February 29 was released to the media.
Trump attributed the spike in the confirmed cases of coronavirus to the large-scale testing of the deadly disease.
The study also found that most GM foods did not disclose the fact on the label. "A few also made false claims of being GM-free," the study by CSE said.
India battles big pharma over cough syrup abuse, reducing supplies
GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues.
Ties between India and the United States have been strained in recent years because of trade policies and patent disputes.
Analysts are divided on the deal valuations. Some say Torrent could have bargained harder, as Sanofi, among others, passed it over.
The next hearing on Pfizer's plea is slated for March 21
Besides opposing the suspension of three medicines, the sector has also questioned the process adopted by the government.
A notice issued by the Indian Health Ministry at the weekend said that a government-appointed committee of experts had found that the banned combinations were "likely to involve risk to human beings, whereas safer alternatives to the said drug are available."
FDI in brownfield investment has resulted in acquisition of domestic drug-manufacturing firms by multinational companies.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances